Portopulmonary hypertension overview

Revision as of 18:26, 24 September 2012 by Shankar Kumar (talk | contribs) (Created page with "__NOTOC__ {{Portopulmonary hypertension}} {{CMG}} ==Overview== Portopulmonary hypertension (PPH) is defined by the coexistence of portal and pulmonary hypertension. PPH i...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Portopulmonary hypertension Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Portopulmonary hypertension from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Portopulmonary hypertension overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Portopulmonary hypertension overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Portopulmonary hypertension overview

CDC on Portopulmonary hypertension overview

Portopulmonary hypertension overview in the news

Blogs on Portopulmonary hypertension overview

Directions to Hospitals Treating Portopulmonary hypertension

Risk calculators and risk factors for Portopulmonary hypertension overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Portopulmonary hypertension (PPH) is defined by the coexistence of portal and pulmonary hypertension. PPH is a serious complication of liver disease, present in 0.25 to 4% of all patients suffering from cirrhosis. Once an absolute contraindication to liver transplantation, it is no longer, thanks to rapid advances in the treatment of this condition.[1] Today, PPH is comorbid in 4-6% of those referred for a liver transplant.[2][3]

References

  1. Kuo PC et al. Portopulmonary Hypertension and the Liver Transplant Candidate. Transplantation 1999;67(8):1087-1093
  2. Torregosa et al. Role of Doppler echos in the assessment of portopulmonary hypertension in liver transplant candidates. Transplantation 2001;71:572-574
  3. Tapper EB, Knowles D, Heffron T, Lawrence EC, Csete M. Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition. Transplant Proc. 2009 Jun;41(5):1969-71.

Template:WH Template:WS